A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

Inclusion Criteria:

• Patients voluntarily participated in the study and signed informed consent;

• Age ≥60 years old, gender unlimited;

• ECOG PS ≤2;

• Expected survival ≥6 months;

• A definitive diagnosis of ITP, including newly diagnosed, chronic, and persistentITP;

• PLT < 30×109/L for at least two consecutive times with an interval of at least 1 daybefore medication

• Patients with laboratory test results meet the following criteria: a. alanineaminotransferase (ALT) 3.0 x or less normal limit (ULN), aspartate aminotransferase (AST) 3.0 x ULN or less; b. Serum total bilirubin ≤1.5×ULN; c. Serum creatinine ≤1.5×ULN;

• The researchers determined that patients could be treated with hexapopal.

Exclusion Criteria:

• Patients who did not respond to previous treatment with herombopag;

• A history of allergy to thrombopoietin receptor agonist (TPO-RA) drugs;

• Combined with other important organ dysfunction, such as liver and kidney failure,cardiac insufficiency, etc.

• Secondary thrombocytopenia, such as rheumatic immune disease, chronic liver disease,hyperlienism, malignant hematologic disease, bone marrow hematopoietic exhaustiondisease (such as AA, MDS), hereditary thrombocytopenia, CVID, drug-inducedthrombocytopenia, etc.;

• Receive TPO-RA medication within 2 weeks prior to treatment;

• Non-steroidal anti-inflammatory drugs (aspirin, salicylate, etc.) and anticoagulants (warfarin, clopidogrel, etc.) should be taken during treatment, which have an impacton platelet function.

• There are severe active bleeding symptoms, such as gastrointestinal bleeding,intracranial bleeding, etc.

• Severe thrombotic disease, such as transient ischemic attack, myocardial infarction,pulmonary embolism, deep vein thrombosis, and disseminated intravascular coagulation (DIC), occurred within 6 months prior to the screening period;

• Have a New York Heart Society (NYHA) Class 3 or 4 congestive heart failure, or havea history of NYHA Class 3/4 congestive heart failure with a left ejection fraction (LVEF) of < 45% within 4 weeks prior to treatment;

• Positive anti-human immunodeficiency virus antibody or anti-treponema pallidumspecific antibody; Hepatitis virus positive, such as HBV, HCV, etc.

• A history of cirrhosis;

• Bone marrow reticulum fiber staining (MF) ≥2 grade;

• Have an active infection that is difficult to control;

• Have a history of or accompanied by malignant tumors;

• Pregnant or lactating women;

• Any other conditions that the investigator determines are not suitable forparticipation in the study.